Abstract: Graves’ ophthalmopathy (GO) is an inflammatory eye disease that develops in the orbit in association with autoimmune thyroid disorders. Symptoms include mainly proptosis and extraocular muscle dysfunction due to involvement of both extraocular muscle and orbital fat.  Corticosteroid theraphy  can relieve GO via both immunomodulation and antiinflammation.   This review focuses on issues of the efficacy, side effects, and indications of corticosteroid therapy given by orally, subconjunctival / retrobulbar injections, versus intravenously. Corticosteroid therapy, when given orally, is more effective than given subconjunctivally, and given intravenously seemed to be the most effective, whereas more side effects in the treatment of GO.  GO should be treated as early as possible, especially in patients with active inflammation to prevent the development or progression of GO.  Corticosteroid therapy should be made in light of the riskbenefit ratio.  (Int Rev Ophthalmol, 2014, 38:   415-419)